How many investments has Cardinal Partners made?

Cardinal Partners has 17 tracked investments, 4 of which have exited via acquisition or IPO.

What stage does Cardinal Partners invest at?

Cardinal Partners invests at the Seed, Series A, Series B, Growth stages.

What sectors does Cardinal Partners focus on?

Cardinal Partners focuses on Biotech, Digital Health, Healthtech, Medical Devices.

Where is Cardinal Partners located?

Cardinal Partners is headquartered in Princeton, US.

Does Cardinal Partners lead rounds?

Yes, Cardinal Partners leads investment rounds.

Who does Cardinal Partners co-invest with?

Cardinal Partners most often shares deals with ARCH Venture Partners, Aspect Ventures, Bessemer Venture Partners, among 39 tracked co-investors.

Cardinal Partners

Venture capital

Princeton · Seed–Growth · 8 people tracked

Also known as CHP MANAGEMENT, INC.

★ Follow + Add to CRM ⤳ Find an introduction

✨ Fox Verdict

Investment thesis

Cardinal Partners focuses on early and growth stage healthcare investing, backing disruptive healthcare technology-enabled services and life sciences companies. The firm often serves as the first institutional investor and occasionally plays a co-founding role at inception. Its thesis is driven by ongoing change across healthcare systems, insurance, and regulatory reform, favoring companies that deliver more care to more people at lower cost. Cardinal emphasizes deep healthcare investing experience, strong academic, clinical, industry, and investment networks, and sustained engagement with portfolio companies to build durable, valuable businesses through multiple economic cycles.

Invests inBiotech Digital Health Healthtech Medical Devices Princeton United States

Source: firm website, verified Aug 25, 2026.

Stage

Seed–Growth

Princeton, New Jersey, US

Leads rounds

Leads

Instruments

Equity

Founded

1996

AUM

$400M

VC funds

Tracked investments

Team · 8 people

from the firm's website & public directories

John Clarke· Managing Partner· Alvin, Texas, United Statesin

John Clarke is a Managing Partner at Cardinal Partners, which he co-founded in 1997, and brings over three decades of early-stage venture capital experience. He leads the firm's life sciences investment practice and has led or directed investments in multiple publicly traded pharmaceutical and healthcare companies. Prior to Cardinal, he spent 15 years at DSV Partners, where he managed the firm's healthcare and life sciences portfolio and served as interim CEO of several successful companies.

j•••@cardinalpartners.comreveal

John Park· Partner & CFO· Philadelphia

John Park is Partner and CFO at Cardinal Partners, which he co-founded in 1997. He entered venture capital in 1992 as CFO of DSV Partners, where he became a General Partner in 1995. Before venture capital, he held financial and analytical roles at Day & Zimmermann, a Philadelphia-based services company, and in the oil and gas industry.

j•••@cardinalpartners.comreveal

Kent Marquardt· General Partner

k•••@cardinalpartners.comreveal

Thomas G. McKinley· General Partner

t•••@cardinalpartners.comreveal

Alan Ezekowitz

Arnold Milstein· Professor of Medicine at Stanford University· Stanford, California

Arnold Milstein is a Professor of Medicine at Stanford University, where he directs the Clinical Excellence Research Center, a collaboration between the Schools of Medicine and Engineering focused on designing health care delivery models that lower per capita spending and improve patient experience. Earlier, he founded a healthcare performance improvement firm later acquired by Mercer and co-founded the Leapfrog Group and the Consumer Purchaser Alliance. He served on the faculty of UCSF's Health Policy Institute, held a term as a MedPAC Commissioner, and holds a BA in Economics from Harvard, an MD from Tufts, and an MPH from UC Berkeley.

Diego Miralles· CEO, Laronde· La Jolla, CA

Diego Miralles, MD, PhD, is CEO of Laronde and previously served as President of Adaptive Therapeutics, where he built a therapeutics program on the Adaptive immunosequencing platform. He spent years at Johnson & Johnson beginning in 2005, working on drug development at Tibotec in Belgium, leading the Janssen Research and Early Development unit in La Jolla, and founding the JLABS incubator (2012) and Janssen Healthcare Innovation (2011). Earlier he held R&D roles at Trimeris and Triangle Pharmaceuticals and was an Assistant Professor at Duke University Medical Center; he holds an MD from the Universidad de Buenos Aires and is an Adjunct Professor of Pharmacology at UC San Diego.

Paul Schimmel· Professor of Biochemistry and Biophysics at MIT

Paul Schimmel is the Ernest and Jean Hahn Professor of Cell and Molecular Biology at The Scripps Research Institute, with campuses in Florida and California. He earned his PhD in biochemistry and biophysics from MIT in 1966 and previously held the John D. and Catherine T. MacArthur Professorship in MIT's Department of Biology. He has authored roughly 500 scientific papers and a three-volume textbook on biophysical chemistry, holds numerous patents, and has cofounded or served as founding director of several biotechnology companies, seven of which became NASDAQ-listed.

What they invest in

from 12 of 19 portfolio companies

Healthtech ×9Biotech ×7Medical Devices ×7Digital Health ×5Enterprise Software ×3AI & Machine Learning ×2SaaS ×2Data & Infrastructure ×1

HQs:United States×10Denmark×1

Investments · 19 tracked

founders shown can be your intro path

By year:2018 · 1 2016 · 1 2015 · 13 dated

aTYR PHARMAatyrpharma.com 𝕏NASDAQ: ATYRMar 2015

aTyr is a clinical-stage biotechnology company developing therapies derived from tRNA synthetase biology to treat fibrosis and inflammation, with its lead candidate efzofitimod in clinical trials for interstitial lung disease.

BiotechHealthtechMedical DevicesSan Diego, US

Paul Schimmel(Non-Management Director)John D. Mendlein(Executive Officer, Director)David Weiner(Executive Officer)Frederic Chereau(Executive Officer)

BoardAmir Nashat(Non-Management Director)inAkkaraju Srinivas(Non-Management Director)

Board seatPaul SchimmelJohn Clarke· per SEC Form D

Co-investorsEcoR1 Capital Sofinnova Ventures Domain Partners Polaris Partners Samsara BioCapital

Healthcare Aquiredteladoc.com in 𝕏NYSE: TDOCJul 2016

Teladoc Health operates a virtual care platform connecting patients with care providers for medical care, mental health, and chronic disease management services.

Digital HealthHealthtechMental HealthPurchase, US

Michael King(Executive Officer)Mark Hirschhorn(Executive Officer)Jason Gorevic(Executive Officer, Director)Kevin Williamson(Executive Officer)Adam Vandervoort(Executive Officer)Daniel Trencher(Executive Officer)

Board seatThomas G. McKinley· per SEC Form D

Co-investorsDria Ventures Harmonic Growth Partners HLM Venture Partners Kleiner Perkins New Capital Partners QuestMark Partners +2 more

Alkermesalkermes.com inNASDAQ: ALKS

Alkermes develops pharmaceutical medicines for psychiatric and neurological disorders, including addiction, serious mental illness, and sleep disorders.

BiotechHealthtechMedical Devices

PartnerJohn Clarke· led

Co-investorsHatteras Venture Partners

Priviahealthpriviahealth.com in 𝕏NASDAQ: PRVA

Privia Health operates a network of physician practices organized for value-based care delivery, supporting independent practices and physicians across multiple specialties while maintaining clinical autonomy.

Data & InfrastructureDigital HealthEnterprise SoftwareHealthtechSaaS

Verastemverastem.com in 𝕏NASDAQ: VSTM

Verastem Oncology is a biopharmaceutical company that discovers and develops drugs to treat cancer patients.

BiotechMedical DevicesNeedham, US

Robert WeinbergAMY C. CAVERS(Executive Officer)CATHY CAREW(Executive Officer)JONATHAN PACHTER(Executive Officer)ROB GAGNON(Executive Officer)BRIAN STUGLIK(Executive Officer, Director)

PartnerJohn Clarke· led

Co-investorsBessemer Venture Partners Foresite Capital Lightstone Ventures Longwood Fund Oberland Capital OrbiMed

Cardinal AnalytxMar 2018SEC filingmedium confidence

Palo Alto, US

Linda T. Hand(Executive Officer, Director)Niall O'Cathasaigh(Executive Officer)

BoardKent Marquardt(Director)Thomas McKinley(Director)Mark Smith(Director)Elizabeth Spaulding(Director)

Board seatJohn Clarke· per SEC Form D · $2M raise · filed Mar 2018

Co-investorsKleiner Perkins

3M3m.com

Alnylamalnylam.com in 𝕏

Alnylam is a biopharmaceutical company that supports investigator-initiated studies in therapeutic areas including transthyretin-mediated amyloidosis, acute hepatic porphyria, and primary hyperoxaluria for medical researchers and healthcare professionals.

BiotechDigital HealthMedical Devices

John Maraganore(Founder)inDr. Yvonne Greenstreetin

Co-investorsARCH Venture Partners Atlas Venture Blackstone Life Sciences

Athenahealth Incathenahealth.com in

Cloud-based healthcare platform for clinical workflows

Bob Segertin

Co-investorsAspect Ventures Bain Capital Double Impact Fund LP Bain Capital Tech Opportunities BCI Draper Associates Mercury Fund +6 more

Cureatrcureatr.com

New York, US

Joseph Mayer(Director)James Bradley(Director)Bharath Ganesan(Director)Richard Resnick(Executive Officer, Director)

BoardJohn Clarke(Director)inTodd Pietri(Director)

Co-investorsWindham Capital Partners Activate Ventures

Ivenixivenix.com in

Ivenix makes an intelligent infusion pump system for hospital settings that delivers intravenous medications to patients while incorporating safeguards to reduce medication errors.

BiotechHealthtechMedical DevicesAmesbury, US

John Sokolowski(Executive Officer)George W. Gray(Executive Officer)Carolyn Malleck(Executive Officer)Jesse Ambrosina(Executive Officer)

BoardKetan Patel(Director)inJohn K. Clarke(Director)in

Co-investorsF-Prime Capital SCP Vitalife Partners ECO Fleet Holdings

Life Imagelifeimage.com in 𝕏acquired by Intelerad

Life Image (now part of Intelerad, a GE HealthCare company) provides technology that connects physicians and moves medical imaging and data across the patient journey.

Digital HealthEnterprise SoftwareHealthtechMedical DevicesNewton, US

Hamid Tabatabaie(Executive Officer, Director, Promoter)

BoardDavid Jahns(Director)Thomas McKinley(Director)William Cowen(Director)in

Co-investorsLRVHealth

Lundbecklundbeck.com

Momentapharmamomentapharma.com

Prealizehealthprealizehealth.com in 𝕏

Prealize develops AI and machine learning solutions for healthcare providers and health plans to enable proactive, prediction-driven care rather than reactive treatment.

AI & Machine LearningDigital HealthHealthtechInsurTechStanford, US

BoardDr. Arnold MilsteinDr. Nigam Shah

Prexton Therapeuticsprextontherapeutics.com inacquired by Lundbeck

Prexton Therapeutics was a biopharmaceutical company developing novel therapies for Parkinson's disease, including its lead mGluR4 modulator candidate foliglurax.

BiotechHealthtechMedical DevicesCopenhagen, DK

Co-investorsM Ventures Seroba Life Sciences Sunstone Capital Ysios Capital

Qpidhealthqpidhealth.com

Sapphire Digitalsapphire-digital.com in 𝕏acquired by Zelis

Enterprise SoftwareFintechHealthtechSaaS

Vividion Therapeuticsvividion.com inacquired by Bayer

Vividion Therapeutics develops small molecule therapeutics using a covalent-first chemoproteomics approach to identify and target previously undruggable proteins.

AI & Machine LearningBiotechDeep TechPrinceton, US

Ben Cravatt(Scientific Founder)Phil Baran(Scientific Founder)Jin-Quan Yu(Scientific Founder)

BoardJohn Park(Executive Officer)John Clarke(Executive Officer, Director)in

Co-investorsARCH Venture Partners Avoro Capital Advisors Nextech Invest SoftBank Vision Fund Versant Ventures

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.

Exits · 9

IPOs and acquisitions across the tracked portfolio

aTYR PHARMANASDAQ: ATYRHealthcare AquiredNYSE: TDOCAlkermesNASDAQ: ALKSPriviahealthNASDAQ: PRVAVerastemNASDAQ: VSTMLife Imageacq. by InteleradPrexton Therapeuticsacq. by LundbeckSapphire Digitalacq. by ZelisVividion Therapeuticsacq. by Bayer

Portfolio news

latest coverage across their companies

Alnylam Stock Sinks As Trial Fears And Targets Fall - TipRanks.com

Alnylam · tipranks.com · Jul 17, 2026

Teladoc Health (NYSE:TDOC): Has the Rebound Gone Too Far?

Healthcare Aquired · kalkinemedia.com · Jul 17, 2026

Alkermes to Report Second Quarter Financial Results on July 28, 2026 - BioSpace

Alkermes · biospace.com · Jul 15, 2026

Here’s What RBC Capital Has to Say About Verastem (VSTM) - Insider Monkey

Verastem · insidermonkey.com · Jul 3, 2026

Ivenix Infusion System Raises $ | SignalBase

Ivenix · trysignalbase.com · Mar 25, 2026

Fund performance · per public LP disclosures

as of Jun 2025

Fund	Vintage	Committed	Net IRR	TVPI	DPI
Cardinal NR Sidecar HoldingsLPs: New York City Fire Department Pension Fund, New York City Board of Education Retirement System	2018	—	17.2%	—	0.45x

Source: public limited-partner disclosures (CalPERS, CalSTRS). Net IRR / TVPI / DPI as reported by the limited partner; a fund's early-year IRR is an interim estimate (J-curve).

Frequently asked questions

How many investments has Cardinal Partners made?: Cardinal Partners has 17 tracked investments, 4 of which have exited via acquisition or IPO.
What stage does Cardinal Partners invest at?: Cardinal Partners invests at the Seed, Series A, Series B, Growth stages.
What sectors does Cardinal Partners focus on?: Cardinal Partners focuses on Biotech, Digital Health, Healthtech, Medical Devices.
Where is Cardinal Partners located?: Cardinal Partners is headquartered in Princeton, US.
Does Cardinal Partners lead rounds?: Yes, Cardinal Partners leads investment rounds.
Who does Cardinal Partners co-invest with?: Cardinal Partners most often shares deals with ARCH Venture Partners, Aspect Ventures, Bessemer Venture Partners, among 39 tracked co-investors.

Images

Similar investors

Amadeus Capital Partners

Amadeus Capital Partners is a technology investment firm that backs founders building complex, science-led and deep tech businesses, supporting them over the long term as they scale internationally.

$50K – $12.7M

B Capital Group

B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.

$10M – $50M

Breyer Capital

Breyer Capital is a venture capital firm that backs high-impact entrepreneurs, making strategic investments guided by founder passion and its network of experienced investors.

$500K – $10M

Capricorn Venture Partners

Capricorn Partners is a Belgium-based, partner-owned independent management company for alternative investment funds, investing in innovative companies across digital, health and clean technologies with an ESG focus.

$270K – $10.8M

DCVC (Data Collective)

DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.

$5M – $25M